Editas Medicine (EDIT) PT Lowered to $60 at Raymond James
Tweet
Share
E-mailGet Alerts EDIT Hot Sheet
Price: $3.08 +0.33%
Rating Summary:
12 Buy, 13 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 30
Rating Summary:
12 Buy, 13 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 30
Join SI Premium – FREE
Raymond James analyst Steven Seedhouse lowered the price target on Editas Medicine (NASDAQ: EDIT) to $60.00 (from $65.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Braze Inc (BRZE) PT Raised to $40 at DA Davidson
- GitLab Inc (GTLB) PT Raised to $55 at DA Davidson, Neutral Rating Maintained
- Credo Tech (CRDO) PT Lowered to $310 at JPMorgan, Overweight Rating Maintained
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
